In patients with a clinical core mismatch, **stent retriever thrombectomy limits the progression of the stroke***



The DAWN™ Trial confirms the benefit of stent retriever thrombectomy with the Trevo Retriever up to 24 hours

Confirming tissue – not only time – can drive patient evaluation in stroke

Trevo™ XP ProVue Retrievers

See package insert for complete indications, complications, warnings, and instructions for use.

INDICATIONS FOR USE

1. The Trevo Retriever is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy with the device should start within 6 hours of symptom onset.
2. The Trevo Retriever is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.
3. The Trevo Retriever is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion of the internal carotid artery (ICA) or middle cerebral artery (MCA)-M1 segments with smaller core infarcts (0-50cc for age < 80 years, 0-20cc for age ≥ 80 years). Endovascular therapy with the device should start within 6-24 hours of time last seen well in patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy.

THIS DOCUMENT IS INTENDED SOLELY FOR THE USE OF HEALTHCARE PROFESSIONALS.

A physician must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that physicians be trained in the use of any particular product before using it in a procedure. The information presented is intended to demonstrate the breadth of Stryker product offerings. A physician must always refer to the package insert, product label and/or instructions for use before using any Stryker product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area. The Stryker products listed above are CE marked according to the Medical Device Directive 93/42/EEC.

*Nogueira RG, et al.; Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. *N Engl J Med.* 2018 Jan 4;378(1):11-21. doi: 10.1056/NEJMoa1706442. Epub 2017 Nov 11.

The Trevo Retriever is not cleared for use up to 24 hours in all countries. Please consult your local Stryker representative or governing agency to confirm.

AP002038 v1.0

Concentric Medical
301 East Evelyn Avenue
Mountain View, CA 94041

Stryker Neurovascular
47900 Bayside Parkway
Fremont, CA 94538

strykerneurovascular.com

Date of Release: MAY/2018
EX_EN_IL_EU

stryker

The **first and only** device indicated to reduce disability in ischemic stroke patients **up to 24 hours**

Trevo™ XP
PROVUE RETRIEVER

With the Trevo™ Retriever, more **patients can be saved** from a lifetime of disability

The Trevo Retriever was the **only device used** in the DAWN™ Trial*

The DAWN Trial demonstrates a **35.5%** absolute benefit with stent retriever thrombectomy



There is no statistical difference in safety endpoints between stent retriever thrombectomy + medical management and medical management alone



Mean procedure time in minutes	**56.0**
Post-procedure mTICI 2b/3	**84.1%** (no rescue therapy allowed)
NNT	**2.8**

The DAWN™ Trial confirms the benefit of stent retriever thrombectomy with the Trevo Retriever up to 24 hours

*Nogueira RG, et al.; Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. *N Engl J Med*. 2018 Jan 4;378(1):11-21. doi: 10.1056/NEJMoa1706442. Epub 2017 Nov 11.

The Trevo™ Retriever is the only device with an indication to **reduce disability up to 24 hours**

A consistent design for clot removal



Trevo XP
ProVue Retriever

Consistent **full-length visibility**

Consistent **tubular design** allows for active deployment (applying forward pressure during deployment)

Consistent **large cells allow clot integration** at any deployment orientation



3mm, 4mm and 6mm retriever sizes for unique patient anatomy